Fresh analysis indicates that patients who discontinue popular GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight far faster than those who halt conventional diet and exercise programs.
Findings released in a prominent medical journal demonstrates that while overweight individuals can lose about a fifth of their body weight while on the medication, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such treatments need to be cognizant of the danger of fast rebound weight gain when the medication ends," stated lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment weight within about 18 months.
Weighing Treatments
The study, which examined dozens of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with conventional dieting.
Scientists emphasize that individuals who shed pounds through dieting typically see a slower creep back—approximately 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists believe the mechanism of the drugs explains the heightened rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the body to produce less of its endogenous hormone, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making overeating a significant risk."
A Lifelong Issue?
Medical guidelines advise the injections for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, due to the likelihood of relapse, the therapy should be considered life-long.
This opinion is supported by pharmaceutical companies, who state that the findings "underscore the long-term character of excess weight," similar to managing conditions like hypertension.
User Testimonies
People who have discontinued the medication report a intense return of appetite.
"It felt as if a switch activating and you're instantly extremely hungry," described a patient.
This challenge is worsened if users have not adopted sustainable lifestyle or habit changes during treatment.
Significant Interest
Figures indicate that millions of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is more common among women compared to males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Finally, researchers caution that while these medications are effective agents for shedding pounds, they are not a standalone fix and long-term success likely depends on integrated behavioural changes.
